1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

HHKEX:8049
2.50
HKD
-0.05
(-1.96%)
733.93MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.82
1.07
0.96
1.17
1.15
1.16
1.15
1.11
1.26
1.5
1.5
1.57
1.61
- -
Basic EPS, GAAP
0.14
0.24
0.21
0.25
0.26
0.29
0.26
0.23
0.26
0.35
0.26
0.33
0.35
- -
Free Cash Flow per Basic Share
- -
0.06
0.25
0.2
0.2
0.19
0.17
0.1
0.22
0.34
0.51
0.37
0.54
- -
Dividend per Share
- -
- -
- -
- -
- -
0.06
0.05
0.03
0.05
0.05
0.51
0.06
0.21
- -
Book Value per Share
0.85
1.08
1.29
1.55
1.8
2.02
2.21
2.4
2.59
2.88
2.64
2.91
3.01
2.83
Tangible Book Value per Share
0.79
1.05
1.26
1.52
1.78
2
2.14
2.33
2.52
2.78
2.55
2.81
2.92
2.82
Basic Weighted Avg Shares
560
560
560
560
560
560
560
560
560
560
560
560
560
560
Sales/Revenue/Turnover
458
602
539
654
645
648
646
622
705
842
842
881
902
- -
Operating Margin (%)
19.91
24.57
23.78
23.9
24.26
23.47
23.07
18.25
19.25
18.28
18.97
20.81
23.8
- -
Depreciation Expense
14
16
19
19
21
20
21
22
29
34
28
27
28
- -
Net Income, GAAP
79
133
118
143
144
161
145
127
143
194
148
184
199
- -
Effective Tax Rate (%)
16.21
16.83
14.62
14.71
16.42
13.47
17.44
15.65
19.17
1.92
25.27
11.06
24.8
- -
Profit Margin (%)
17.32
22.07
21.82
21.81
22.38
24.89
22.41
20.34
20.31
23
17.61
20.91
22.05
- -
Working Capital
220
397
523
672
800
927
1,011
392
318
1,053
476
238
280
496
LT Debt
8
8
3
2
2
1
- -
- -
- -
- -
72
- -
- -
75
Total Equity
474
606
724
867
1,011
1,133
1,239
1,345
1,454
1,612
1,480
1,630
1,688
1,585
Return on Invested Capital (%)
17.65
23.77
17.34
17.92
15.49
15.01
12.02
9.86
10.42
12.91
9.6
11.85
12.27
- -
Return on Capital (%)
17.98
24.24
17.5
17.83
15.33
15.01
12.19
9.83
10.25
12.65
9.36
11.4
11.79
- -
Return on Common Equity (%)
18.27
24.59
17.69
17.94
15.38
15.04
12.21
9.8
10.24
12.63
9.58
11.85
11.99
- -

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
8
8
LT Borrowings
- -
72
75
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
560
560
560
Market Capitalization
669
835
683

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
1,201
1,163
Cash, Cash Equivalents & STI
- -
656
646
Accounts Receivable, Net
- -
268
274
Inventories
- -
103
82
Total Current Liabilities
- -
725
667
Payables & Accruals
- -
- -
- -
ST Debt
- -
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.09%
4.89%
3.61%
Free Cash Flow
16.88%
49.88%
44.3%
Net Income, GAAP
6.85%
11.43%
7.94%
Sales/Revenue/Turnover
- -
- -
2.35%
Total Cash Common Dividend
15,008.42%
226.01%
239.37%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
881
2025
- -
- -
902
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.33
2025
- -
- -
0.35
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.06
2025
- -
- -
0.21
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hong Zhang
Full Time Employees
1,107
Sector
Health technology
Industry
Pharmaceuticals: other
Address
31 Beishan Street, Chaoyang Town, Huinan County Tonghua JL China 135100
IPO Date
May 24, 2001
Website
jlchanglong.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK) manufactures and distributes traditional Chinese medicines and bio-pharmaceutical products. The company produces a range of herbal medicines, including patented formulations such as Changlong Brand Huinanchanglong Tablets for respiratory conditions; bio-extracts and granules for digestive and immune health; antibiotic alternatives derived from natural sources; and veterinary pharmaceuticals for livestock in the agricultural sector. It operates primarily through research, production, and sales segments, targeting domestic markets in China with a focus on Jilin Province and expanding into national distribution networks. Founded in 2001 and headquartered in Huinan County, Jilin Province, China, the company maintains production facilities in the same region, leveraging local herbal resources for bio-pharmacy development. Its business spans the pharmaceutical and biotechnology industries, serving hospitals, pharmacies, and agribusiness customers across mainland China. Changlong emphasizes quality control under Chinese GMP standards and invests in R&D for innovative herbal extracts. In recent developments, the company announced a strategic partnership with regional biotech firms in 2024 to enhance production capacity for new bio-extract lines, amid ongoing expansions in veterinary products. It completed a funding round in late 2023 to support facility upgrades and launched an expanded range of immune-boosting herbal supplements in early 2025, responding to post-pandemic market demands. No major acquisitions or name changes were reported in the last two years, with operations remaining stable under current management.